Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro

Genetics and Molecular Research

Volumn 14, Issue 2, 2015, Pages 5630-5641

  Wang, Y ^a   Yin, C ^a   Feng, L ^a   Wang, C ^a   Sheng, G ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Acute monocytic leukemia; CD47; Cytarabine; Leukemia stem cells; Monoclonal antibody

Indexed keywords

CD47 ANTIGEN; CYTARABINE; IMMUNOGLOBULIN G; CD47 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ACUTE MONOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CELL POPULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LONG TERM SURVIVAL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHARMACOLOGICAL BLOCKING; TARGET CELL; ANIMAL; CELL DIFFERENTIATION; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; LEUKEMIA, MONOCYTIC, ACUTE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ARA; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD47; CELL DIFFERENTIATION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTARABINE; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; MACROPHAGES; MICE; NEOPLASTIC STEM CELLS; PHAGOCYTOSIS; PROGNOSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930005811     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.May.25.15     Document Type: Article

References (38)

1. Adams GP and Weiner LM (2005). Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23: 1147-1157.
2. Barclay AN and Brown MH (2006). The SIRP family of receptors and immune regulation. Nat. Rev. Immunol. 6: 457-464.
3. Brown EJ and Frazier WA (2001). Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11: 130-135.
4. Chao MP, Alizadeh AA, Tang C, Myklebust JH, et al. (2010). Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699-713.
5. Chao MP, Alizadeh AA, Tang C, Jan M, et al. (2011). Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71: 1374-1384.
6. Chiba T, Kita K, Zheng YW, Yokosuka O, et al. (2006). Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44: 240-251.
7. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, et al. (2012). Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl. Acad. Sci. U. S. A. 109: 6656-6661.
8. Goodell MA, Brose K, Paradis G, Conner AS, et al. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183: 1797-1806.
9. Gorman MF, Ji L, Ko RH, Barnette P, et al. (2010). Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr. Blood Cancer 55: 421-429.
10. Guan Y, Gerhard B and Hogge DE (2003). Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101: 3142-3149.
11. Guo Y, Follo M, Geiger K, Lübbert M, et al. (2003). Side-population cells from different precursor compartments. J. Hematother. Stem Cell Res. 12: 71-82.
12. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, et al. (2006). Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24: 506-513.
13. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, et al. (2006). Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 107: 293-300.
14. Hosen N, Park CY, Tatsumi N, Oji Y, et al. (2007). CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 104: 11008-11013.
15. Hussain SZ, Strom SC, Kirby MR, Burns S, et al. (2005). Side population cells derived from adult human liver generate hepatocyte-like cells in vitro. Dig. Dis. Sci. 50: 1755-1763.
16. Inaba H, Fan Y, Pounds S, Geiger TL, et al. (2008). Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer 113: 522-529.
17. Jaiswal S, Jamieson CH, Pang WW, Park CY, et al. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138: 271-285.
18. Jiang P, Lagenaur CF and Narayanan V (1999). Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J. Biol. Chem. 274: 559-562.
19. Jin L, Hope KJ, Zhai Q, Smadia-Joffe F, et al. (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12: 1167-1174.
20. Jordan CT and Guzman ML (2004). Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 23: 7178-7187.
21. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, et al. (2000). The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777-1784.
22. Kaspers GJ and Zwaan CM (2007). Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 92: 1519-1532.
23. Kayo H, Yamazaki H, Nishida H, Dang NH, et al. (2007). Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma. Biochem. Biophys. Res. Commun. 364: 808-814.
24. Komuro H, Saihara R, Shinya M, Takita J, et al. (2007). Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J. Pediatr. Surg. 42: 2040-2045.
25. Lane SW and Gilliland DG (2010). Leukemia stem cells. Semin. Cancer Biol. 20: 71-76.
26. Lindberg FP, Gresham HD, Schwarz E and Brown EJ (1993). Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. J. Cell Biol. 123: 485-496.
27. Majeti R, Chao MP, Alizadeh AA, Pang WW, et al. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138: 286-299.
28. Matozaki T, Murata Y, Okazawa H and Ohnishi H (2009). Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol. 19: 72-80.
29. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, et al. (2009). Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 23: 25-42.
30. Monaco G, Konopleva M, Munsell M, Leysath C, et al. (2004). Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 22: 188-201.
31. Ravandi F and Estrov Z (2006). Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin. Cancer Res. 12: 340-344.
32. Setoguchi T, Taga T and Kondo T (2004). Cancer stem cells persist in many cancer cell lines. Cell Cycle 3: 414-415.
33. Testa U (2011). Leukemia stem cells. Ann. Hematol. 90: 245-271.
34. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, et al. (1980). Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26: 171-176.
35. van Rhenen A, van Dongen GA, Kelder A, Rombuouts EJ, et al. (2007). The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110: 2659-2666.
36. Wang JC and Dick JE (2005). Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15: 494-501.
37. Woods WG (2006). Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr. Blood Cancer 46: 565-569.
38. Zhou S, Morriss JJ, Barnes Y, Lan L, et al. (2002). Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 99: 12339-12344.